Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled Murepavadin to EnBiotix

PRESS RELEASE | Allschwil, Switzerland, September 1, 2021 – Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, today announced that the companies have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock. The transaction is subject to a number of closing conditions, including approval by Polyphor and EnBiotix shareholders, satisfactory completion of due diligence and satisfactory assessment of tax consequences. Following closing, expected in Q4 2021, Polyphor will be renamed and is expected to trade under a new ticker symbol on the Swiss Stock Exchange.

Full Press Release | September 1st, 2021

EnBiotix Reports Publication Highlighting Anti-persister Agent Targeting Antibiotic-Tolerant Infections in Antimicrobial Agents and Chemotherapy

PRESS RELEASE | CAMBRIDGE, Mass. and LEIPZIG, Germany (October 2nd, 2017) – EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, announced today a publication in Antimicrobial Agents & Chemotherapy , a journal of the American Society for Microbiology, detailing data on EBX-001, the Company’s lead product for the treatment of Pseudomonas aeruginosa infections. The paper titled, “An Anti-Persister Strategy for the Treatment of Chronic Pseudomonas aeruginosa Infections,” was co-authored by a team of scientists from Massachusetts General Hospital, Harvard Medical School, the Geisel School of Medicine at Dartmouth and EnBiotix.

Full Press Release at BusinessWire | October 2nd, 2017

EnBiotix Acquires Anti-Microbial Peptide Portfolio from AMP Therapeutics GmbH

PRESS RELEASE | CAMBRIDGE, Mass. and LEIPZIG, Germany (November 3, 2016) – EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, today announced the completion of an asset acquisition of AMP Therapeutics GmbH (“AMPT”), an anti-microbial peptide portfolio company of Boerhinger Ingelheim Venture Fund and Novartis Venture Fund. In connection with the acquisition, EnBiotix has established EnBiotix GmbH. EnBiotix has also initiated a collaboration with Leipzig University and AMPT’s scientific co-founder, Professor Ralf Hoffmann, Ph.D.

Full Press Release at BusinessWire | November 3rd, 2016

Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology

PRESS RELEASE | GREENFIELD, Ind. & CAMBRIDGE, Mass. – Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix’s engineered phage technology in specific animal health targets. If successful, this endeavor could result in potential alternatives for traditional antibiotics in animals.

This collaboration furthers Elanco’s commitment to aggressively seek and develop antibiotic alternatives as outlined in our comprehensive antibiotic stewardship plan,” said Jeff Simmons, President, Elanco Animal Health. “Innovative research will be key to protecting both human and animal health while safeguarding antibiotics for future generations.”

Full Press Release at BusinessWire | June 16th, 2016

EnBiotix to Collaborate with Mayo Clinic on Engineered Phage Program

PRESS RELEASE |CAMBRIDGE, Mass. – EnBiotix, Inc., a product-focused bioengineering company transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant and drug-tolerant bacterial infections, today announced a new collaboration with Mayo Clinic to continue development of  the company’s drug candidate EPP-001, an engineered bacteriophage product to deliver biofilm dispersing enzymes to treat Staphylococcus aureus (S. aureus) infections in prosthetic joints. In addition, EnBiotix received a funding award from Mayo Clinic Ventures which is helping to facilitate the project. The research program team will be supervised by Robin Patel, M.D., Director, Infectious Diseases Research Laboratory, Mayo Clinic, and Chair, Division of Clinical Microbiology, Mayo Clinic and Govind Rajagopalan Ph.D., Associate Professor of Immunology, and conducted at both Mayo Clinic and EnBiotix laboratories. 

Full Press Release at BusinessWire| June 13th, 2016

EnBiotix, Inc. Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development

PRESS RELEASE | CAMBRIDGE, Mass.–EnBiotix, Inc. announced today that it is a Grand Challenges Explorations (“GCE”) winner, an initiative funded by the Bill & Melinda Gates Foundation. The EnBiotix team will pursue an innovative global health and development research project entitled “Integrated Systems Biology for Phage/Microbiome Modeling” for the generation and visualization of novel network models highlighting host-microbe interactions and the subnetworks most altered by phage therapy. The approach should yield an enhanced understanding of the effect of the gut microbiome on the development a variety diseases involving disruptions in the microbiome and ultimately aid in the development of precision phage therapies for environmental enteric dysfunction in children.

Full Press Release at BusinessWire| May 26th, 2016